AstraZeneca Pharma India is currently trading at RS. 8769.55, up by 41.05 points or 0.47% from its previous closing of RS. 8728.50 on the BSE.

The stock opened at RS. 8756.45 and touched an intraday high of RS. 8769.55 and a low of RS. 8693.70. A total of 154 shares have been traded so far.

A BSE group 'A' stock with a face value of RS. 2, AstraZeneca Pharma India reached a 52-week high of RS. 10653.05 on June 13, 2025, and a 52-week low of RS. 6222.35 on November 21, 2024. Over the last week, the stock’s high and low were RS. 8993.95 and RS. 8675.00, respectively. The company’s market capitalization currently stands at RS. 21923.88 crore.

The company’s shareholding pattern shows 75.00% held by promoters, 7.58% by institutions, and 17.42% by non-institutions.

AstraZeneca Pharma India is gearing up to launch Eculizumab (Soliris) in August 2025 in India. This drug is indicated for treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Earlier, the company had secured Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (Soliris).

AstraZeneca Pharma India is a leading global biopharmaceutical company engaged in the discovery, development, and commercialization of medicines in key healthcare areas, including cardiovascular/metabolic diseases, cancer, and respiratory, inflammatory, and autoimmune disorders. It operates through two segments — Healthcare and Clinical Trial.